Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Commentary|Articles|July 23, 2026
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Advertisement
Advertisement
The
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement